- Dupilumab (Dupixent) is associated with clinical improvement and is well tolerated in real-world patients with moderate to severe atopic dermatitis (AD).
Why this matters
- Real-world data are needed to confirm evidence from clinical trials.
- Dupilumab was associated with improved clinical disease severity in 86% of patients.
- 30% experienced complete clearance.
- 56% experienced partial but stable improvement.
- 95% of patients receiving dupilumab also used topical or systemic medications during their treatment.
- 26% of patients treated with dupilumab experienced adverse events.
- None were serious adverse events.
- The most common adverse effects were dry eyes, conjunctivitis, and keratitis.
- The most common reasons for discontinuation were adverse events and no/minimal improvement in disease activity.
- 77 patients with AD treated with dupilumab were included.
- Funding: None.
- Retrospective study.
- Small patient sample size.